Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Short Interest Update

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 61,520 shares, a growth of 31.5% from the December 15th total of 46,799 shares. Based on an average trading volume of 55,407 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.8% of the company’s shares are sold short. Currently, 0.8% of the company’s shares are sold short. Based on an average trading volume of 55,407 shares, the days-to-cover ratio is presently 1.1 days.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. Wall Street Zen upgraded Burning Rock Biotech from a “hold” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Burning Rock Biotech

Several institutional investors have recently made changes to their positions in the company. Prospera Financial Services Inc purchased a new position in shares of Burning Rock Biotech in the 3rd quarter worth about $214,000. China Universal Asset Management Co. Ltd. bought a new stake in Burning Rock Biotech in the third quarter worth about $26,000. Finally, Crcm LP boosted its stake in Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after acquiring an additional 26,809 shares during the last quarter. Institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Stock Down 3.9%

Shares of Burning Rock Biotech stock traded down $1.31 on Friday, hitting $32.01. The company had a trading volume of 26,546 shares, compared to its average volume of 35,806. The stock has a market capitalization of $344.46 million, a price-to-earnings ratio of -19.28 and a beta of 1.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.91 and a current ratio of 3.14. Burning Rock Biotech has a 1 year low of $2.18 and a 1 year high of $34.79. The stock has a 50 day moving average of $19.64 and a 200-day moving average of $12.15.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.